Go Deep
Marksans Pharma Limited
Marksans Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,785 | 29.1 | 4.97 | 0.11 | 331.65 |
| Oct 2026 | 20,839 | 27.1 | 4.63 | 0.11 | 309.10 |
Marksans Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 8,407,960,000.0 | 8,561,140,000.0 | 7,544,270,000.0 | 7,204,090,000.0 |
| Net Profit | 1,571,670,000.0 | 1,481,290,000.0 | 1,132,020,000.0 | 982,500,000.0 |
| EPS | 3.5 | 3.3 | 2.5 | 2.2 |
Marksans Pharma Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 29,416,430,000.0 | 26,144,450,000.0 | 21,741,950,000.0 | 18,496,190,000.0 | — |
| Net Profit | 4,179,000,000.0 | 3,805,750,000.0 | 3,137,000,000.0 | 2,663,080,000.0 | — |
| EPS | 9.2 | 8.4 | 6.9 | 6.4 | — |
Marksans Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 38,609,020,000.0 | 32,396,320,000.0 | 26,809,530,000.0 | 21,903,890,000.0 | — |
| Total Liabilities | 8,082,220,000.0 | 7,502,500,000.0 | 5,950,470,000.0 | 4,253,170,000.0 | — |
| Total Equity | 30,231,560,000.0 | 24,669,120,000.0 | 20,650,540,000.0 | 17,451,620,000.0 | — |
Owes vs Owns
Marksans Pharma Limited owed ₹0.21 for every ₹1 it owned in Mar 2026, up from ₹0.19 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.21× | 0.23× | 0.22× | 0.19× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Marksans Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 25.6%Receivables 16.7%Inventory 25.2%Fixed assets (tangible) 24.4%Intangible assets 4.2%Other assets 3.9%
How it's funded — Mar 2026
Short-term debt 0.8%Long-term debt 7.0%Payables 8.7%Other liabilities 4.4%Shareholders' equity 79.1%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 989.3 | 704.6 | 700.2 | 715.1 |
| Receivables | 644.6 | 540.0 | 453.2 | 416.8 |
| Inventory | 972.3 | 845.5 | 617.9 | 484.7 |
| Fixed assets (tangible) | 941.2 | 899.8 | 693.2 | 392.8 |
| Intangible assets | 162.0 | 113.7 | 104.3 | 109.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 151.5 | 136.0 | 112.1 | 71.6 |
| Liabilities & equity | ||||
| Short-term debt | 29.6 | 23.1 | 29.1 | 41.6 |
| Long-term debt | 270.1 | 263.3 | 190.0 | 65.7 |
| Payables | 336.9 | 305.7 | 268.3 | 230.6 |
| Other liabilities | 171.6 | 158.1 | 107.7 | 87.4 |
| Shareholders' equity | 3,052.7 | 2,489.4 | 2,085.9 | 1,765.1 |
| Net tangible assets | 2,861.1 | 2,353.3 | 1,960.8 | 1,635.9 |
Marksans Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 4,581,250,000.0 | 2,066,640,000.0 | 2,304,070,000.0 | 2,374,120,000.0 | — |
| Investing Activities | -2,482,670,000.0 | -490,090,000.0 | -1,408,400,000.0 | -2,592,120,000.0 | — |
| Financing Activities | -709,280,000.0 | -651,460,000.0 | -687,270,000.0 | 1,978,290,000.0 | — |